128 related articles for article (PubMed ID: 7035323)
1. Effect of metoclopramide on plasma aldosterone in normal subjects, primary aldosteronism and hypopituitarism.
Mantero F; Opocher G; Boscaro M; Valpione E; Armanini D; Fallo F
Horm Metab Res; 1981 Aug; 13(8):464-7. PubMed ID: 7035323
[TBL] [Abstract][Full Text] [Related]
2. Effects of metoclopramide, a dopamine antagonist, on secretion of aldosterone and renin release in patients with primary aldosteronism.
Mizuno K; Yamazaki M; Ikeda K; Yaginuma K; Hashimoto S; Fukuchi S
Jpn Heart J; 1983 Nov; 24(6):917-24. PubMed ID: 6323781
[TBL] [Abstract][Full Text] [Related]
3. The effect of pizotifen, a serotonin antagonist, and of pirenzepine, a muscarinic antagonist, on hormonal responses to metoclopramide in healthy subjects.
Jungmann E; Althoff PH; Hermann GJ; Schöffling K
Arzneimittelforschung; 1984; 34(9):1022-4. PubMed ID: 6391497
[TBL] [Abstract][Full Text] [Related]
4. Effects of metoclopramide and bromocriptine on the renin-angiotensin-aldosterone system in man. Dopaminergic control of aldosterone.
Carey RM; Thorner MO; Ortt EM
J Clin Invest; 1979 Apr; 63(4):727-35. PubMed ID: 438333
[TBL] [Abstract][Full Text] [Related]
5. [The effect of dopaminergic antagonists on plasma aldosterone in normal subjects and patients with hypopituitarism].
Shikuma R; Yoshimura M; Takashina R; Yamazaki H; Kambara S; Ijichi H
Nihon Naibunpi Gakkai Zasshi; 1984 Sep; 60(9):1041-5. PubMed ID: 6394371
[TBL] [Abstract][Full Text] [Related]
6. Mineralocorticoid and prolactin response to the dopamine antagonist metoclopramide in patients with primary aldosteronism.
Witzgall H; von Werder K; Weber PC
J Steroid Biochem; 1983 Nov; 19(5):1671-6. PubMed ID: 6645503
[TBL] [Abstract][Full Text] [Related]
7. Hyper-responsiveness of aldosterone to metoclopramide in aldosteronism.
Gniadek TC; Grekin RJ; Gross MD; Villareal JZ
Clin Endocrinol (Oxf); 1982 May; 16(5):475-81. PubMed ID: 7044619
[No Abstract] [Full Text] [Related]
8. Dopaminergic modulation of aldosterone secretion: effect of sodium balance and postural changes.
García-Robles R; Ruilope L; Mancheño E; Hurtado A; Alcázar JM; Varela C; de la Calle H; Rodicio JL; Sancho J
Rev Esp Fisiol; 1984 Mar; 40(1):63-8. PubMed ID: 6087430
[TBL] [Abstract][Full Text] [Related]
9. Normokalemic hyperaldosteronism in patients with resistant hypertension.
Benchetrit S; Bernheim J; Podjarny E
Isr Med Assoc J; 2002 Jan; 4(1):17-20. PubMed ID: 11802302
[TBL] [Abstract][Full Text] [Related]
10. Circadian rhythm of plasma aldosterone concentration in patients with primary aldosteronism.
Kem DC; Weinberger MH; Gomez-Sanchez C; Kramer NJ; Lerman R; Furuyama S; Nugent CA
J Clin Invest; 1973 Sep; 52(9):2272-7. PubMed ID: 4353776
[TBL] [Abstract][Full Text] [Related]
11. Differing effects of metoclopramide and adrenocorticotropin on plasma aldosterone levels in glucocorticoid-suppressible hyperaldosteronism and other forms of hyperaldosteronism.
Ganguly A; Pratt JH; Weinberger MH; Grim CE; Fineberg NS
J Clin Endocrinol Metab; 1983 Aug; 57(2):388-92. PubMed ID: 6306041
[TBL] [Abstract][Full Text] [Related]
12. [Effect of diazoxide on blood pressure, PRA and plasma aldosterone in hypertensive patients (author's transl)].
Mantero F; Perini A; Armanini D; Gion M; Opocher G; Boscaro M
G Ital Cardiol; 1976; 6(7):1246-53. PubMed ID: 1010235
[TBL] [Abstract][Full Text] [Related]
13. [Lack of effect of aging on dopaminergic inhibition of aldosterone and prolactin increase].
Preis P; Luger A; Templ H; Tragl HK; Geyer G
Z Gerontol; 1985; 18(4):241-3. PubMed ID: 3901563
[TBL] [Abstract][Full Text] [Related]
14. Pituitary peptides other than ACTH may not be aldosterone secretagogue in primary aldosteronism.
Miyamori I; Koshida H; Matsubara T; Soma R; Takasaki H; Okamoto S; Takeda R
Exp Clin Endocrinol; 1990 Aug; 95(3):323-9. PubMed ID: 2174003
[TBL] [Abstract][Full Text] [Related]
15. Dopamine reduces aldosterone and 18-hydroxycorticosterone response to angiotensin II in patients with essential low-renin hypertension and idiopathic hyperaldosteronism.
Witzgall H; Lorenz R; von Werder K; Weber PC
Clin Sci (Lond); 1985 Mar; 68(3):291-9. PubMed ID: 3882312
[TBL] [Abstract][Full Text] [Related]
16. Ratio of serum aldosterone to plasma renin concentration in essential hypertension and primary aldosteronism.
Trenkel S; Seifarth C; Schobel H; Hahn EG; Hensen J
Exp Clin Endocrinol Diabetes; 2002 Apr; 110(2):80-5. PubMed ID: 11928071
[TBL] [Abstract][Full Text] [Related]
17. Endogenous dopaminergic inhibition of aldosterone and prolactin secretion is apparently not increased in primary aldosteronism.
Jungmann E; Althoff PH; Rosak C; Schwedes U; Schöffling K
Horm Metab Res; 1986 Feb; 18(2):138-40. PubMed ID: 3699687
[TBL] [Abstract][Full Text] [Related]
18. [The effect of metoclopramide, a dopamine inhibitor, on aldosterone secretion in patients with primary aldosteronism].
Mizuno K; Yaginuma K; Yamazaki M; Fukuchi S
Nihon Naibunpi Gakkai Zasshi; 1982 Aug; 58(8):976-83. PubMed ID: 6292008
[No Abstract] [Full Text] [Related]
19. Serum aldosterone response to metoclopramide in normal subjects and acromegalic patients.
Zacharieva S; Stoeva I; Matrozov P; Andonova K
Exp Clin Endocrinol; 1990 Aug; 95(3):331-8. PubMed ID: 2245821
[TBL] [Abstract][Full Text] [Related]
20. Regulation of aldosterone secretion in primary aldosteronism.
Vetter H; Vetter W
Horm Metab Res; 1975 Sep; 7(5):418-24. PubMed ID: 1183923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]